Supportive Care in Cancer

, Volume 25, Issue 3, pp 801–809 | Cite as

Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types

  • Jeong Eun Kim
  • Joung-Soon JangEmail author
  • Jae-Weon Kim
  • Yong Lee Sung
  • Chi-Heum Cho
  • Myung-Ah Lee
  • Do-Jin Kim
  • Myung-Ju Ahn
  • Kil Yeon Lee
  • Sun Jin Sym
  • Myong Choel Lim
  • Hun Jung
  • Eun Kim Cho
  • Kyung Wan Min
Original Article



This study evaluated the efficacy and safety of a 3-day aprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the first cycle of non-anthracycline plus cyclophosphamide (AC)-based moderately emetogenic chemotherapy (MEC) based on government guidelines in Korean patients.


This multicenter, randomized, double-blind, phase IV trial (NCT01636947) enrolled adult South Korean patients with a broad range of tumor types who were scheduled to receive a single dose of ≥1 MEC agent. Patients were randomized to a 3-day regimen of aprepitant (aprepitant regimen) or placebo (control regimen) on top of ondansetron plus dexamethasone. The primary and key secondary efficacy endpoints were the proportions of subjects who achieved no vomiting and complete response (CR) during the overall phase.


Of the 494 randomized subjects, 480 were included in the modified intent-to-treat population. Response rates for no vomiting and CR in the overall phase were numerically higher for the aprepitant regimen compared with the control regimen groups, but failed to reach statistical significance (no vomiting 77.2 vs 72.0%; p = 0.191; CR 73.4 vs 70.4%; p = 0.458). Both the aprepitant and control regimens were generally well tolerated.


A 3-day aprepitant regimen was numerically better but not statistically superior to a control regimen with respect to the achievement of no vomiting or CR during the overall phase in a non-AC MEC Korean population based on government reimbursement guidelines.


Aprepitant Neurokinin-1 receptor antagonists Moderately emetogenic chemotherapy, Chemotherapy-induced nausea and vomiting 



We would like to thank DreamCIS, Inc., for providing clinical research services for this study. Medical writing and editorial assistance was provided by Maxwell Chang and Traci Stuve of ApotheCom, Yardley, PA, with funding provided by Merck & Co., Inc., Kenilworth, NJ.

Author contributions

Jeong Eun Kim, Joung-Soon Jang, and Kyung Wan Min are responsible for the work described in this paper. All authors were involved in at least one of the following: conception, design, acquisition, analysis, statistical analysis, interpretation of data and drafting the manuscript and/or revising the manuscript for important intellectual content. Jae-Weon Kim, Myong Choel Lim, Kil Yeon Lee, and Sun Jin Sym were also responsible for provision of study materials or patients. All authors provided final approval of the version to be published.

Compliance with ethical standards

Conflict of interest

Hun Jung, Cho Eun Kim, and Kyung Wan Min are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., who may potentially own stock and/or hold stock options in the company. The remainder of the authors has nothing to disclose.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Supplementary material

520_2016_3463_MOESM1_ESM.docx (27 kb)
ESM 1 (DOCX 27 kb)


  1. 1.
    Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH (1983) On the receiving end—patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203–208CrossRefPubMedGoogle Scholar
  2. 2.
    Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MH (1996) On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189–195CrossRefPubMedGoogle Scholar
  3. 3.
    Grunberg SM, Boutin N, Ireland A, Miner S, Silveira J, Ashikaga T (1996) Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer 4:435–439CrossRefPubMedGoogle Scholar
  4. 4.
    Grunberg SM, Slusher B, Rugo HS (2013) Emerging treatments in chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol 11:1–18PubMedGoogle Scholar
  5. 5.
    National Comprehensive Cancer Network, Inc. NCCN (2014) Clinical Practice Guidelines in Oncology. Antiemesis. Version 1.2014. National Comprehensive Cancer Network Web siteGoogle Scholar
  6. 6.
    Richardson JL, Marks G, Levine A (1988) The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 6:1746–1752PubMedGoogle Scholar
  7. 7.
    Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(suppl 5):v232–v243CrossRefPubMedGoogle Scholar
  8. 8.
    Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822–2830CrossRefPubMedGoogle Scholar
  9. 9.
    Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18:423–431CrossRefPubMedGoogle Scholar
  10. 10.
    Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie MG, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3098CrossRefPubMedGoogle Scholar
  11. 11.
    Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de W R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the aprepitant protocol 052 study group. J Clin Oncol 21:4112–4119CrossRefPubMedGoogle Scholar
  12. 12.
    Gralla RJ, De Wit R, Herrstedt J, Carides AD, Ianus J, Guoguang-Ma J, Evans JK, Horgan KJ (2005) Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials. Cancer 104:864–868CrossRefPubMedGoogle Scholar
  13. 13.
    Roila F, Herrstedt J, Aapro M, et al. for the ESMO/MASCC Guidelines Working Group (2013) MASCC/ESMO antiemetic guideline 2013. Multinational Association of Supportive Care in Cancer. Accessed February 9, 2016.
  14. 14.
    Jordan K, Gralla R, Jahn F, Molassiotis A (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197–202CrossRefPubMedGoogle Scholar
  15. 15.
    Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189–4198CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Health Insurance Review & Assessment Services (2015) Oncology medicine reimbursement guideline.Google Scholar
  17. 17.
    Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26:1081–1090CrossRefPubMedGoogle Scholar
  18. 18.
    Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL, Dakhil SR, Moore T, Fitch TR (2005) 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 6:765–772CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, de P G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261–2268CrossRefPubMedGoogle Scholar
  20. 20.
    Gralla RJ, Rapoport BL, Jordan K, Street JC, Carides A (2010) Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: analysis of 1,872 patients (pts) in prospective randomized clinical phase III trials (RCTs). J Clin Oncol 28(15 suppl):9057Google Scholar
  21. 21.
    Ryu JW, Park SJ, Park MS, Kim JS, Lee KY (2013) The use of aprepitant in the first cycle of moderately emetogenic chemotherapy in patients with colorectal cancer: its preventive effect on chemotherapy-induced nausea and vomiting. Korean J Clin Oncol 9:47–52CrossRefGoogle Scholar
  22. 22.
    Tanioka M, Kitao A, Matsumoto K, Shibata N, Yamaguchi S, Fujiwara K, Minami H, Katakami N, Morita S, Negoro S (2013) A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 109:859–865CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Ito Y, Karayama M, Inui N, Kuroishi S, Nakano H, Nakamura Y, Yokomura K, Toyoshima M, Shirai T, Masuda M, Yamada T, Yasuda K, Hayakawa H, Suda T, Chida K (2014) Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer 84:259–264CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Jeong Eun Kim
    • 1
  • Joung-Soon Jang
    • 2
    Email author
  • Jae-Weon Kim
    • 3
  • Yong Lee Sung
    • 4
  • Chi-Heum Cho
    • 5
  • Myung-Ah Lee
    • 6
  • Do-Jin Kim
    • 7
  • Myung-Ju Ahn
    • 8
  • Kil Yeon Lee
    • 9
  • Sun Jin Sym
    • 10
  • Myong Choel Lim
    • 11
  • Hun Jung
    • 12
  • Eun Kim Cho
    • 12
  • Kyung Wan Min
    • 12
  1. 1.Department of OncologyAsan Medical Center, University of Ulsan College of MedicineSeoulSouth Korea
  2. 2.Department of Internal MedicineChung-Ang University College of MedicineSeoulSouth Korea
  3. 3.Department of Obstetrics and GynecologySeoul National University College of MedicineSeoulSouth Korea
  4. 4.Division of Respiratory and Critical Care Medicine, Department of Internal MedicineKorea University College of MedicineSeoulSouth Korea
  5. 5.Department of Obstetrics and Gynecology, School of MedicineKeimyung UniversityDaeguSouth Korea
  6. 6.Department of Medical OncologySeoul St. Mary’s Hospital, The Catholic University of KoreaSeoulSouth Korea
  7. 7.Division of Allergy and Respiratory Medicine, Department of Internal MedicineSoonchunhyang University Bucheon Hospital, Soonchunhyang University College of MedicineBucheonSouth Korea
  8. 8.Division of Hematology-Oncology, Department of Medicine, The Samsung Medical CenterSungkyunkwan University School of MedicineSeoulSouth Korea
  9. 9.Department of SurgeryKyung Hee University School of MedicineSeoulSouth Korea
  10. 10.Division of Hematology and Medical Oncology, Department of Internal MedicineGachon University Gil Medical Center, Incheon Regional Cancer Center, Gachon University School of MedicineIncheonSouth Korea
  11. 11.Gynecologic Cancer Branch, Research Institute and HospitalNational Cancer CenterGyeonggi-doSouth Korea
  12. 12.Merck Sharp & DohmeSeoulSouth Korea

Personalised recommendations